The FDA has approved Anzupgo (delgocitinib) cream for the topical treatment of moderate to severe chronic hand eczema in ...

Benefits of 7000 steps per day include lower risk for death and cardiovascular disease, diabetes, dementia, and depression.

RFK Jr may remove all 16 members of the advisory group that helps decide which preventive services are fully covered by insurance.

Tildrakizumab is an interleukin-23 antagonist approved under the brand name Ilumya for the treatment of plaque psoriasis.

With new systemic treatments now available for psoriatic disease, questions remain on the comparable efficacy and safety of these therapies.

Nearly half of all Planned Parenthood patients use Medicaid to pay for services. Medicaid is the federal health care program for people with low incomes or disabilities. In her ruling, Talwani ...

The FDA is recommending that certain products containing 7-hydroxymitragynine be subject to the Controlled Substances Act.

The FDA has appointed George Francis Tidmarsh, MD, PhD, to be the director of the Center for Drug Evaluation and Research.

A broad spectrum of systemic inflammatory manifestations defines VEXAS syndrome, with cutaneous, respiratory, and vascular involvement commonly reported.

A consensus-based definition for on-treatment remission for patients with plaque psoriasis has been published by the National Psoriasis Foundation.

The loved ones of those with cancer report an emotional burden, including concerns about life expectancy, course of treatment, and pain.

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.